| AGX reference price and market capitalization | $570.43 closing price on July 31, 2026 and $8.00 billion reported market capitalization | StockAnalysis AGX overview and statistics | August 3, 2026 |
| Price cross-validation | $570.43 closing price confirmed by StockAnalysis and FinancialContent for July 31, 2026 | StockAnalysis and FinancialContent market data | August 3, 2026 |
| Market capitalization verification | $7.997 billion calculated as $570.43 x 14.02 million shares versus $8.00 billion reported; 0.03% difference | financial_rigor.py market cap verification and SEC Form 10-Q | August 3, 2026 |
| Shares outstanding | 14,019,247 common shares outstanding as of May 29, 2026; StockAnalysis reports 14.02 million | Argan Q1 FY2027 Form 10-Q and StockAnalysis statistics | August 3, 2026 |
| FY2026 revenue and net income | $944.606 million revenue and $137.774 million net income in the audited Form 10-K, cross-validated with StockAnalysis at $944.61 million and $137.77 million | Argan FY2026 Form 10-K and StockAnalysis financials | August 3, 2026 |
| TTM results through April 30, 2026 | TTM revenue about $1.04 billion and TTM net income about $161.29 million, with TTM diluted EPS of $11.38 | StockAnalysis financials and statistics, period ending April 30, 2026 | August 3, 2026 |
| Q1 FY2027 operating results | $290.954 million revenue, $61.114 million gross profit, $46.063 million net income, and $3.24 diluted EPS for the quarter ended April 30, 2026, beating consensus of $2.33 EPS and $256.03 million revenue | Argan Q1 FY2027 Form 10-Q and company earnings release | August 3, 2026 |
| Cash, investments, debt, and net cash | $355.847 million cash plus $617.708 million investments, $9.58 million reported debt, and about $963.98 million net cash at April 30, 2026 | Argan Q1 FY2027 Form 10-Q and StockAnalysis statistics | August 3, 2026 |
| Project backlog | $2.8 billion at April 30, 2026, compared with $2.9 billion at January 31, 2026 and over $2.7 billion at January 31, 2026 in the annual report | Argan Q1 FY2027 Form 10-Q and FY2026 Form 10-K | August 3, 2026 |
| Valuation calculation | 50.13x PE, 16.89x PB, 16.42x P/FCF, 6.09% FCF yield, and 0.35% dividend yield using $570.43, $11.38 EPS, $33.77 book value per share, $34.73 FCF per share, and $2.00 annual dividend | financial_rigor.py valuation verification and StockAnalysis statistics | August 3, 2026 |
| Technical snapshot | 50-day moving average $655.24, 200-day moving average $487.27, RSI 44.31, average 20-day volume 343,311, and 52-week range $197.00 to $805.75 | StockAnalysis AGX statistics and price history | August 3, 2026 |
| Short interest | 909,517 shares short at 6.49% of shares outstanding, up from 645,245 in the prior month | StockAnalysis AGX statistics | August 3, 2026 |
| Analyst consensus | Buy consensus with 5 analysts and an average price target of $679.80, about 19% above the July 31, 2026 close | StockAnalysis AGX forecast | August 3, 2026 |
| Management and capital allocation | David H. Watson has served as CEO since August 2022; the repurchase authorization was increased to $200 million in April 2026, and the company declared a $0.50 quarterly dividend on June 10, 2026 | Argan management profile, company release, and SEC Form 10-Q | August 3, 2026 |